Scarica l'app Stockscreener
8.02
3.08%
0.24
Pre-mercato:
8.09
0.07
+0.87%
Precedente Chiudi:
$7.78
Aprire:
$7.76
Volume 24 ore:
695.36K
Relative Volume:
0.44
Capitalizzazione di mercato:
$473.95M
Reddito:
$192.64M
Utile/perdita netta:
$2.51M
Rapporto P/E:
153.05
EPS:
0.0524
Flusso di cassa netto:
$12.42M
1 W Prestazione:
+4.02%
1M Prestazione:
+13.92%
6M Prestazione:
+69.20%
1 anno Prestazione:
+80.22%
Intervallo 1D:
$7.76
$8.065
Intervallo di 1 settimana:
$7.59
$8.27
Portata 52W:
$3.8092
$9.60
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
Nome
Vanda Pharmaceuticals Inc
Settore
Industria
Telefono
202-734-3400
Indirizzo
2200 PENNSYLVANIA AVE NW, WASHINGTON
Confronta VNDA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
8.02 | 459.77M | 192.64M | 2.51M | 12.42M | 0.0524 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-05 | Iniziato | B. Riley Securities | Buy |
| 2024-10-31 | Iniziato | H.C. Wainwright | Buy |
| 2024-07-11 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-02-25 | Downgrade | Jefferies | Buy → Hold |
| 2021-05-12 | Iniziato | BofA Securities | Buy |
| 2021-01-14 | Downgrade | Citigroup | Buy → Neutral |
| 2020-10-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-06-09 | Downgrade | Citigroup | Buy → Neutral |
| 2020-03-16 | Downgrade | Oppenheimer | Perform → Underperform |
| 2020-03-12 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-11-07 | Downgrade | Citigroup | Buy → Neutral |
| 2019-08-01 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-07-25 | Downgrade | Stifel | Buy → Hold |
| 2018-12-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2018-12-04 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2018-12-04 | Reiterato | Jefferies | Buy |
| 2018-11-08 | Ripresa | Jefferies | Buy |
| 2018-09-21 | Ripresa | Oppenheimer | Outperform |
| 2018-05-23 | Iniziato | Citigroup | Buy |
| 2018-01-19 | Iniziato | Seaport Global Securities | Buy |
| 2017-09-14 | Reiterato | Piper Jaffray | Overweight |
| 2017-06-27 | Ripresa | Piper Jaffray | Overweight |
| 2017-05-26 | Iniziato | H.C. Wainwright | Buy |
| 2017-04-12 | Iniziato | Oppenheimer | Outperform |
| 2016-11-09 | Iniziato | Aegis Capital | Buy |
| 2016-10-06 | Ripresa | Jefferies | Buy |
Mostra tutto
Vanda Pharmaceuticals Inc Borsa (VNDA) Ultime notizie
Earnings Report: Can Vanda Pharmaceuticals Inc ride the EV waveForecast Cut & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc.VNDA - yourwyominglink.com
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc.VNDA - marketscreener.com
Vanda Pharmaceuticals (NASDAQ:VNDA) Shares Cross Above Two Hundred Day Moving AverageHere's Why - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceuticals Inc.VNDA - Chartmill
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceuticals Inc.VNDA - FinancialContent
Vanda Stock Drop 10% Premarket After FDA Rejects Jet Lag Drug Application - MSN
Millennium Management LLC Reduces Stake in Vanda Pharmaceuticals Inc - GuruFocus
VNDA: Imminent launches and label expansions position the portfolio for major near-term growth - TradingView — Track All Markets
Lost Money on Vanda Pharmaceuticals Inc. (VNDA)? Contact Levi & Korsinsky About Fraud Investigation - marketscreener.com
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Short Interest Down 52.3% in December - MarketBeat
Loss Report: How Vanda Pharmaceuticals Inc stock benefits from tech adoptionShort Setup & Weekly High Potential Alerts - Bộ Nội Vụ
Revenue Check: Why Vanda Pharmaceuticals Inc stock remains a top recommendationPortfolio Gains Summary & Fast Gain Stock Tips - Bộ Nội Vụ
Vanda (VNDA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Finviz
Retail Trends: Will Vanda Pharmaceuticals Inc stock attract more institutional investorsProfit Target & Technical Confirmation Trade Alerts - Bộ Nội Vụ
Aug Retail: Why Vanda Pharmaceuticals Inc stock remains a top recommendation2025 Technical Overview & Weekly Consistent Profit Watchlists - Bộ Nội Vụ
Published on: 2026-01-12 16:11:40 - Улправда
What sentiment indicators say about Vanda Pharmaceuticals Inc. stockMarket Sentiment Summary & Weekly High Potential Stock Alerts - Улправда
Published on: 2026-01-08 21:09:38 - ulpravda.ru
Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder - Sahm
Can Vanda Pharmaceuticals Inc. (VM4) stock surprise markets with earningsJuly 2025 Spike Watch & Reliable Breakout Forecasts - ulpravda.ru
Is Vanda Pharmaceuticals Inc. stock affected by interest rate hikes2025 Historical Comparison & Fast Entry and Exit Trade Plans - ulpravda.ru
Is Vanda Pharmaceuticals Inc. stock positioned well for digital economyEarnings Recap Report & Reliable Entry Point Alerts - ulpravda.ru
Is Vanda Pharmaceuticals Inc. (VM4) stock good for long term investingWeekly Risk Report & Low Drawdown Trading Techniques - ulpravda.ru
Vanda Pharmaceuticals (VNDA) Faces FDA Setback on HETLIOZ Application - GuruFocus
FDA rejects Vanda's jet lag drug application days after approving motion sickness drug - The Business Journals
How Vanda Pharmaceuticals Inc. stock performs in high volatility marketsJuly 2025 Sector Moves & Low Risk High Win Rate Picks - ulpravda.ru
Vanda Pharmaceuticals (VNDA) Faces Setback with FDA Rejection - GuruFocus
Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter o - GuruFocus
Vanda falls as FDA rejects jet lag drug (VNDA:NASDAQ) - Seeking Alpha
Vanda Pharmaceuticals (VNDA) Shares Fall After FDA Decision - GuruFocus
Vanda Faces FDA Setback on HETLIOZ Jet Lag Application - TipRanks
Vanda Stock Drops 10% Premarket After FDA Rejects Jet Lag Drug Application - Stocktwits
Vanda Pharmaceuticals stock falls after FDA rejects jet lag treatment application - Investing.com Canada
Vanda Pharmaceuticals Inc Receives FDA Decision on HETLIOZ® sNDA for Jet Lag - TradingView
Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder – Company AnnouncementFT.com - Financial Times
Vanda Pharmaceuticals Inc. (VNDA) Stock Analysis: Evaluating a 59.54% Potential Upside Amidst Strong Revenue Growth - DirectorsTalk Interviews
Vanda Pharma says FDA is in violation of FDCA regarding its Hetlioz sNDA - The Pharma Letter
Q1 EPS Estimate for Vanda Pharmaceuticals Raised by Analyst - MarketBeat
FDA Approves Vanda Pharma Motion Sickness Drug, Fuels Upside - Benzinga
Biggest stock movers Wednesday: Vanda Pharmaceuticals, Axsome Therapeutics and Cybin - MSN
HC Wainwright Analysts Raise Earnings Estimates for VNDA - MarketBeat
FDA Grants Approval to Vanda Pharma’s Motion Sickness Medication, Boosting Growth Potential - Bitget
Assessing Vanda Pharmaceuticals (VNDA) Valuation After FDA Approval Of NEREUS For Motion Sickness - Yahoo Finance
VIX Spike: Can Vanda Pharmaceuticals Inc VM4 stock surprise markets with earningsJuly 2025 Analyst Calls & Capital Efficiency Focused Ideas - moha.gov.vn
VNDA: HC Wainwright & Co. Raises Price Target to $22, Maintains Buy Rating | VNDA Stock News - GuruFocus
Gastric Motility Disorder Drugs Market is expected to reach US$ - openPR.com
Vanda Pharmaceuticals (NASDAQ:VNDA) Upgraded to "Hold" at Wall Street Zen - MarketBeat
US FDA approves Vanda Pharmaceuticals' motion sickness drug - ET Pharma
Vanda Pharmaceuticals: SG&A Takes Off, TAM Doesn’t (Rating Downgrade) (VNDA) - Seeking Alpha
Vanda Pharmaceuticals Inc Azioni (VNDA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.09%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):